On Thursday, Immunome received an upgrade to its Relative Strength (RS) Rating, from 65 to 78.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating of at least 80 in the early stages of their moves. See if Immunome can continue to show renewed price strength and hit that benchmark.
Immunome is not currently showing a potential entry point. See if the stock goes on to build a promising consolidation that could kick off a new price move.
The company showed 0% earnings growth in its most recent report. Revenue increased 70%.
The company earns the No. 224 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
